A Prospective, One-Arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

This phase two open-label study is designed to assess the safety and efficacy of using Zanubrutibin, a selective next-generation covalent BTK inhibitor, to treat immune thrombocytopenia. Zanubrutinib was developed by a company in China to be a stronger BTK inhibitor with less side effects. Eligible participants include adult patients with confirmed persistent or chronic ITP who have a platelet count less than 30,000µL and demonstrate corticosteroid resistance and failure to respond to at least one approved second-line therapy. The study is looking to enroll 30 participants.



Status: Recruiting

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo